Last reviewed · How we verify
oxybutynin, tolterodine, solifenacin
oxybutynin, tolterodine, solifenacin is a Small molecule drug developed by China Medical University Hospital. It is currently FDA-approved. Also known as: Ditropan, tartrate, vesicare.
Oxybutynin, tolterodine, and solifenacin are marketed drugs primarily used to treat overactive bladder symptoms, with a strong presence in the urology segment. A key strength is their well-established mechanism of action and extensive clinical history, which supports their widespread use and acceptance. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | oxybutynin, tolterodine, solifenacin |
|---|---|
| Also known as | Ditropan, tartrate, vesicare |
| Sponsor | China Medical University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Deprescribing dRrugs for Overactive Bladder in General Practice (DROP) (NA)
- The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial (PHASE3)
- Efficacy of Low-Intensity Shockwave Therapy in Treating Radiation Cystitis (EARLY_PHASE1)
- Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
- A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)
- Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics (PHASE4)
- Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder (PHASE4)
- A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oxybutynin, tolterodine, solifenacin CI brief — competitive landscape report
- oxybutynin, tolterodine, solifenacin updates RSS · CI watch RSS
- China Medical University Hospital portfolio CI
Frequently asked questions about oxybutynin, tolterodine, solifenacin
What is oxybutynin, tolterodine, solifenacin?
Who makes oxybutynin, tolterodine, solifenacin?
Is oxybutynin, tolterodine, solifenacin also known as anything else?
What development phase is oxybutynin, tolterodine, solifenacin in?
Related
- Manufacturer: China Medical University Hospital — full pipeline
- Also known as: Ditropan, tartrate, vesicare
- Compare: oxybutynin, tolterodine, solifenacin vs similar drugs
- Pricing: oxybutynin, tolterodine, solifenacin cost, discount & access